tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Budde K et al. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 1998 Transplant. Proc. pmid:9723280
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Peeters P et al. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. 1998 Transplant. Proc. pmid:9723301
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. 1998 Transplant. Proc. pmid:9723303
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Behr TM et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. 1998 Transplant. Proc. pmid:9723333
Berweck S et al. Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9723345
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Curtis JJ Posttransplant hypertension. 1998 Transplant. Proc. pmid:9723370
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Donadio C et al. Tubular damage and impairment of renal function in transplanted kidneys. 1998 Transplant. Proc. pmid:9723381
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Vanrenterghem Y Tacrolimus (FK 506) in kidney transplantation. 1998 Transplant. Proc. pmid:9723431
Busuttil RW and Holt CD Tacrolimus is superior to cyclosporine in liver transplantation. 1998 Transplant. Proc. pmid:9723432
Jonas S et al. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. 1998 Transplant. Proc. pmid:9723433
Perego C et al. Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. 1998 Transplant. Proc. pmid:9723434
Yonan NA et al. Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. 1998 Transplant. Proc. pmid:9723443
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Fritsche L et al. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. 1998 Transplant. Proc. pmid:9723451
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Thielke J et al. Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. 1998 Liver Transpl Surg pmid:9724482
Reddy SS and Holley JL Nocardiosis in a recently transplanted renal patient. 1998 Clin. Nephrol. pmid:9725785
Garcia-Cozar FJ et al. Two-site interaction of nuclear factor of activated T cells with activated calcineurin. 1998 J. Biol. Chem. pmid:9727000
Snyder SH et al. Immunophilins in the nervous system. 1998 Neuron pmid:9728910
Gammie JS et al. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. 1998 Exp. Hematol. pmid:9728927
Winter C et al. MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. 1998 Brain Res. pmid:9729383
Horning NR et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. 1998 J. Heart Lung Transplant. pmid:9730424
Reichart B et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. 1998 J. Heart Lung Transplant. pmid:9730426
Meiser BM et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. 1998 J. Heart Lung Transplant. pmid:9730427
Kawahara K et al. Tracheal transplantation for carinal reconstruction in dogs. 1998 J. Thorac. Cardiovasc. Surg. pmid:9731780
Cogill JL et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. 1998 Clin. Chem. pmid:9732981
Sussman MA et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. 1998 Science pmid:9733519
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501
Allen C et al. Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. 1998 Sep-Oct Bioconjug. Chem. pmid:9736490